下调和上调
生物
癌症研究
mTORC2型
黑色素瘤
塞鲁美替尼
mTORC1型
细胞生物学
PI3K/AKT/mTOR通路
MEK抑制剂
MAPK/ERK通路
激酶
遗传学
信号转导
基因
作者
Luca Ponzone,Valentina Audrito,Claudia Landi,Enrico Moiso,Chiara Levra Levron,Sara Ferrua,Aurora Savino,Nicoletta Vitale,Massimiliano Gasparrini,Lidia Avalle,Lorenza Vantaggiato,Enxhi Shaba,Beatrice Tassone,Stefania Saoncella,Francesca Orso,Daniele Viavattene,Eleonora Marina,Irene Fiorilla,Giulia Burrone,Youssef Abili
标识
DOI：10.1186/s12943-024-02010-1
摘要
The main drawback of BRAF/MEK inhibitors (BRAF/MEKi)-based targeted therapy in the management of BRAF-mutated cutaneous metastatic melanoma (MM) is the development of therapeutic resistance. We aimed to assess in this context the role of mTORC2, a signaling complex defined by the presence of the essential RICTOR subunit, regarded as an oncogenic driver in several tumor types, including MM.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
YamDaamCaa
kk99123
23
CAOHOU
打卡下班
yar
鸣笛
哈基米德
Zoo
shiqiang mu
风清扬
www
ED
超帅连虎
是羽曦呀
半夏
方翔
SYLH
昏睡的蟠桃
馒头
皖公网安备34019202002308
